Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Peter Ordentlich - CSO Anjali Ganguli - CBO Conference Call Participants Phil Nadeau - TD Cowen Anupam Rama - JPMorgan Ashiq Mubarack - Citi Brad Canino - Stifel Michael Schmidt - Guggenheim Peter Lawson - Barclays William Wood - B. Riley Securities Justin Zelin - BTIG Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Madhu Kumar - Goldman Sachs Eva Privitera - TD Cowen Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Peter Lawson - Barclays Kalpit Patel - B. Riley ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Briggs Morrison - President and Head, R&D Keith Goldan - Chief Financial Officer Dr. Peter Ordentlich - Chief Scientific Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Omari Baruti - Goldman Sachs Phil Nadeau - Cowen and Company Priyanka Grover - JPMorgan Ashiq Muba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (State or Other J ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 CORPORATE PRESENTATION | JANUARY 2023 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwar ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 CORPORATE PRESENTATION | JANUARY 2023 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwar ...

Revumenib Data Update Call with Dr. Ghayas Issa and Dr. Eytan Stein Syndax 參 DECEMBER 11TH, 2022 – ASH ANNUAL MEETING Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All st ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 3Q22 INVESTOR PRESENTATION – NOVEMBER 3, 2022 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identif ...